Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Findley, L. J.
Right arrow Articles by Cleeves, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Findley, L. J.
Right arrow Articles by Cleeves, L.
NEUROLOGY 1985;35:1784
© 1985 American Academy of Neurology

Phenobarbitone in essential tremor

Leslie J. Findley, MD and Lynn Cleeves, PhD

From the Regional Centre for Neurology and Neurosurgery, Oldchurch Hospital, Romford, Essex; and the MRC Neuro-Otology Unit, Institute of Neurology, National Hospital, Queen Square, London, UK.

We conducted a double-blind, placebo-controlled trial of phenobarbitone on a fixed-dose regimen in 12 patients with essential tremor. The drug was better than placebo on accelerometric measurement and clinical assessment, but not according to patient self-assessment or measures of manual performance. Phenobarbitone may be an alternative to beta-adrenoreceptor antagonists in treating essential tremor.

Address correspondence and reprint requests to Dr. Findley, MRC Neuro-Otology Unit, Institute of Neurology, National Hospital, Queen Square, London WC1N 3BG, UK.

Accepted for publication April 5, 1985.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.